Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026
Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026
Company Drug

Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study

Fineline Cube Jan 22, 2026
Company Deals Medical Device

MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal

Fineline Cube Jul 2, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has...

Company Deals

Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen

Fineline Cube Jul 2, 2024

Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...

Company Drug

Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval

Fineline Cube Jul 1, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...

Company Deals

Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum

Fineline Cube Jul 1, 2024

A number of healthcare companies are seeking to capitalize on the recovering market conditions by...

Company Drug

Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer

Fineline Cube Jul 1, 2024

Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China

Fineline Cube Jul 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration

Fineline Cube Jul 1, 2024

Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...

Company Deals Digital

Winning Health Partners with Unicom Digitization Medical to Boost Medical Industry Innovation

Fineline Cube Jul 1, 2024

Winning Health (SHE: 300253), a Shanghai-based company in the medical information industry, has entered into...

Company Drug

BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer

Fineline Cube Jul 1, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...

Company Deals

Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D

Fineline Cube Jul 1, 2024

Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered...

Company Drug

Staidson Pharmaceutical’s Bemiltenase Alfa Earns Orphan Drug Designation from US FDA for Hemophilia Treatment

Fineline Cube Jul 1, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...

Company Deals

Cigna & CMB Life Insurance Partners with Cleveland Clinic Foundation to Enhance Medical Diagnosis for Chinese Patients

Fineline Cube Jul 1, 2024

Cigna & CMB Life Insurance Co., a joint venture between Cigna Corporation, a U.S.-based global...

Company Drug

Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal

Fineline Cube Jul 1, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Drug

IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma

Fineline Cube Jul 1, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...

Company Deals Drug

Yunnan Baiyao Group Secures Global Rights to Kyinno Biotechnology’s Antibody Drug KA-1641

Fineline Cube Jul 1, 2024

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Policy / Regulatory

China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan

Fineline Cube Jul 1, 2024

The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment...

Company Drug

Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints

Fineline Cube Jul 1, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...

Company Drug

CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer

Fineline Cube Jul 1, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Reckitt’s New Shanghai R&D Center to Boost Innovation in Health and Hygiene Products

Fineline Cube Jul 1, 2024

Reckitt (LON: RKT), a UK-based manufacturer of consumer health and hygiene products, is planning to...

Company Drug

Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis

Fineline Cube Jul 1, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...

Posts pagination

1 … 284 285 286 … 612

Recent updates

  • HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod
  • Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe
  • Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer
  • Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy
  • Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Company R&D

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.